CytoSorbents Corp (CTSO)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.35+0.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CTSO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -86.7% |
| Our one-year growth estimate | diamond | 19.6% |
Growth built into the price is above our model estimate.
The price assumes 106.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
CTSO — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, CytoSorbents Corporation issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.*
Why it matters: More clinical uses are key for CytoSorbents to grow money and market share.
Supportive ifQuarterly revenue from key clinical uses is higher than in past quarters.
Worry ifQuarterly revenue stays the same or goes down in key clinical applications.
Why it matters: Germany is a key market. Growth here signals recovery from recent sales declines.
Supportive ifSales in Germany grow by at least 10% quarter over quarter.
Worry ifSales in Germany decline further or remain flat.
Why it matters: The earnings report will show if CytoSorbents can improve its financial performance. Investors will look for signs of recovery.
Watch forThe earnings report shows revenue growth or smaller losses than last quarter.
Also watch forThe earnings report shows more losses or less revenue than last quarter.
Why it matters: Fixing the Nasdaq compliance issue is important to keep the listing. It affects investor trust and capital access.
Worry ifNasdaq confirms compliance with listing rules before the deadline.
Less concerning ifMore notices or actions from Nasdaq about delisting.
Why it matters: Sales growth in Germany is key for overall revenue and market presence.
Supportive ifSales in Germany grow by more than 10% quarter over quarter.
Worry ifSales in Germany decline further or remain flat despite new sales hires.
Why it matters: Stable sales in Germany are key for revenue growth. They show the restructuring works.
Supportive ifSales in Germany show no further decline and ideally start to grow again by early 2027.
Worry ifSales in Germany keep declining. This shows the restructuring is not working.
Why it matters: Getting back in line with Nasdaq is important to keep the stock listed. This impacts how investors feel.
Worry ifThe company needs a minimum bid price of $1.00 for 10 days before September 28.
Less concerning ifThe stock price remains below $1.00 without regaining compliance by September 28.
Why it matters: The results will guide the next steps for FDA approval, a key growth driver.
Watch forThe FDA gave good feedback in meetings about more data for DrugSorb-ATR.
Also watch forNegative feedback or requests for more data could delay the submission process.
Why it matters: Fixing compliance issues would help the stock and boost investor trust.
Supportive ifCytoSorbents has a market value of at least $35 million.
Worry ifMore notices from Nasdaq about not following rules.
Why it matters: If healthcare sector growth speeds up, it could help CytoSorbents improve its performance. It shows the market is strengthening.
Supportive ifHealthcare sector revenue growth speeds up to 10% or more.
Worry ifHealthcare sector revenue growth continues to slow or stays below 10%.
Why it matters: Reaching this goal would lower financial risk and help the company's future.
Supportive ifOperating cash burn drops below $200,000 for two straight quarters.
Worry ifOperating cash burn goes up or stays above $200,000.
Why it matters: Stable or rising revenue is important for the company's growth story. It shows demand for key clinical uses.
Supportive ifQ2 revenue shows growth or stabilizes compared to Q1.
Worry ifQ2 revenue declines further from Q1.
Why it matters: Reaching this goal would help the company’s money situation.
Supportive ifOperating cash flow turns positive in the second half of 2026.
Worry ifOperating cash flow remains negative or worsens in the second half of 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$302 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $844 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,883 loss on $10,000 · 68.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.